NasdaqCM - Nasdaq Real Time Price USD

SELLAS Life Sciences Group, Inc. (SLS)

1.5600
-0.1200
(-7.14%)
At close: May 9 at 4:00:00 PM EDT
1.5700
+0.01
+(0.64%)
After hours: May 9 at 7:59:28 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
1,000
7,600
Cost of Revenue
100
--
0
100
200
Gross Profit
900
--
0
900
7,400
Operating Expense
31,513
31,513
37,869
32,850
26,994
Operating Income
-31,513
-31,513
-37,869
-31,950
-19,594
Net Non Operating Interest Income Expense
632
632
525
317
6
Other Income Expense
4,949
--
4
-9,668
-1,348
Pretax Income
-30,881
-30,881
-37,340
-41,301
-20,936
Tax Provision
--
--
--
0
-237
Net Income Common Stockholders
-30,881
-30,881
-37,340
-41,301
-20,699
Diluted NI Available to Com Stockholders
-30,881
-30,881
-37,340
-41,301
-20,699
Basic EPS
-0.67
-0.50
-1.34
-2.13
-1.34
Diluted EPS
-0.67
-0.50
-1.34
-2.13
-1.34
Basic Average Shares
50,406.6380
61,202.4120
27,777.1110
19,395.7090
15,481.1130
Diluted Average Shares
50,406.6380
61,202.4120
27,777.1110
19,395.7090
15,481.1130
Total Operating Income as Reported
-31,513
-31,513
-37,869
-41,950
-25,294
Total Expenses
31,513
31,513
37,869
32,950
27,194
Net Income from Continuing & Discontinued Operation
-30,881
-30,881
-37,340
-41,301
-20,699
Normalized Income
-30,881
-30,881
-37,344
-31,633
-19,366.2596
Interest Income
632
632
525
317
6
Net Interest Income
632
632
525
317
6
EBIT
-31,513
-31,513
-37,869
-31,950
-19,594
EBITDA
-31,513
-31,513
-37,869
-31,950
-19,594
Reconciled Cost of Revenue
100
--
0
100
200
Net Income from Continuing Operation Net Minority Interest
-30,881
-30,881
-37,340
-41,301
-20,699
Total Unusual Items Excluding Goodwill
4,949
--
4
-9,668
-1,348
Total Unusual Items
4,949
--
4
-9,668
-1,348
Normalized EBITDA
-31,513
-31,513
-37,873
-22,282
-18,246
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
-15.2596
12/31/2021 - 3/12/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VSTM Verastem, Inc.
7.17
+3.31%
 
CRDF Cardiff Oncology, Inc.
2.6600
+1.14%
 
ICU SeaStar Medical Holding Corporation
1.2450
+0.40%
 
CAPR Capricor Therapeutics, Inc.
6.34
-9.04%
 
ALT Altimmune, Inc.
5.59
-3.62%
 
ATOS Atossa Therapeutics, Inc.
0.8167
+0.85%
 
VNDA Vanda Pharmaceuticals Inc.
3.9500
-6.40%
 
AVXL Anavex Life Sciences Corp.
8.25
-3.62%
 
GLSI Greenwich LifeSciences, Inc.
9.43
-2.38%
 
ITRM Iterum Therapeutics plc
1.0200
-2.86%